New notes presented today showed that Zometa(R) (zoledronicacid) offered a meaningful anticancer benefit for premenopausal women withhormone-sensitive, early-stage breast cancer. The study found that Zometawhen added to hormone therapy, following surgery, significantly reduced therisk of cancer returning...